

ID NO: 9, a CDR2H region of, SEQ ID NO: 10, and a CDR1H region of SEQ ID NO: 11, and in the light chain variable domain a CDR3L region of SEQ ID NO: 12, a CDR2L region of SEQ ID NO: 13, and a CDR1L region of SEQ ID NO: 14, and wherein

5

iii) the bispecific antibody comprises a constant heavy chain region of human IgG1 subclass comprising the mutations I253A, H310A, and H435A and the mutations L234A, L235A and P329G (numberings according to EU Index of Kabat.

10 In one aspect, the disclosure refers to a liquid pharmaceutical formulation comprising:

- 120 mg/ml $\pm$ 18 mg/ml of a bispecific anti-human vascular endothelial growth factor (VEGF)/Angiopoietin-2 (ANG2) antibody,

15 - 15 to 35 mM of sodium chloride,

- 15 to 25 mM of a histidine acetate buffer,

- 7.0 mM $\pm$ 2.0 mM methionine,

- 0.03% to 0.07% (w/v) polysorbate 20,

at a pH of 5.5 $\pm$ 0.2;

20 wherein the bispecific anti-VEGF/ANG2 antibody is faricimab; and

wherein the formulation is essentially free of arginine and calcium chloride.

Patent Claims

1. A liquid pharmaceutical formulation comprising:
 - 120 mg/ml $\pm$ 18 mg/ml of a bispecific anti-human vascular endothelial growth factor (VEGF)/Angiopoietin-2 (ANG2) antibody,
 - 5 - 15 to 35 mM of sodium chloride,
 - 15 to 25 mM of a histidine acetate buffer,
 - 7.0 mM $\pm$ 2.0 mM methionine,
 - 0.03% to 0.07% (w/v) polysorbate 20,
 - at a pH of 5.5 $\pm$ 0.2;
- 10 wherein the bispecific anti-VEGF/ANG2 antibody is faricimab; and
wherein the formulation is essentially free of arginine and calcium chloride.
2. The pharmaceutical formulation according to claim 1 for intravitreal administration.
3. The pharmaceutical formulation according to claim 1 or 2, wherein the
15 formulation is essentially free of visible particles.
4. The pharmaceutical formulation according to any one of claims 1 to 3, wherein the formulation further comprises
 - 160 mM $\pm$ 24 mM sucrose.
5. The pharmaceutical formulation according to any one of claims 1 to 4, wherein
20 the formulation has a viscosity of 20 mPas or less.
6. The pharmaceutical formulation according to any one of claims 1 to 5, wherein the formulation has a turbidity of 30 FTU or less.
7. The pharmaceutical formulation according to any one of claims 1 to 6, wherein the formulation has an ionic strength between 20 and 50.

8. The pharmaceutical formulation according to any one of claims 1 to 7, wherein the high molecular weight species (HMW) content of the bispecific antibody in the pharmaceutical formulation is below 10% after 8 weeks at 25°C or after 52 weeks at 25°C.
- 5 9. The pharmaceutical formulation according to any one of claims 1 to 8, wherein the osmolality of the formulation is 300±100 mOsm/kg.
- 10 10. The pharmaceutical formulation according to any one of claims 1 to 9 for use in the treatment of an ocular vascular disease.
- 10 11. The pharmaceutical formulation for use according to claim 10, wherein the ocular vascular disease is selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), macular degeneration, wet age-related macular degeneration (wet AMD), retinopathy of prematurity (ROP), neovascular glaucoma, retinitis pigmentosa (RP), retinal angiomatous proliferation, macular telangiectasia, ischemic retinopathy, iris
15 neovascularization, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, and retinal degeneration.
- 20 12. Use of the pharmaceutical formulation according to any one of claims 1 to 9 in the manufacture of a medicament for the treatment of an ocular vascular disease.
- 25 13. The use of claim 12, wherein the ocular vascular disease is selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), macular degeneration, wet age-related macular degeneration (wet AMD), retinopathy of prematurity (ROP), neovascular glaucoma, retinitis pigmentosa (RP), retinal angiomatous proliferation, macular telangiectasia, ischemic retinopathy, iris
neovascularization, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, and retinal
30 degeneration.
14. The pharmaceutical formulation for use according to claim 11, or the use according to claim 13, wherein the ocular vascular disease is selected from the group consisting of diabetic retinopathy (DR), diabetic macular edema (DME),

retinal vein occlusion (RVO), central retinal vein occlusion (CRVO) and wet age-related macular degeneration (wet AMD).

15. The use of claim 12 or 13, wherein the pharmaceutical formulation is to be administered intravitreally.
- 5 16. A method for the preparation of the pharmaceutical formulation of any one of claims 1 to 9,

the method comprising the steps of

-buffer exchange of the bispecific antibody bulk solution a) against a
10 diafiltration buffer by ultra-filtration and diafiltration or b) by dialysis using a dialysis buffer, the buffers containing a histidine-acetate buffer or a histidine-acetate buffer and sodium chloride, or a histidine-acetate buffer, sodium chloride and methionine, or a histidine-acetate buffer, sodium chloride, methionine and sucrose

- concentration of the buffer exchanged bulk solution by ultrafiltration

15 - adjustment of the final composition of the pharmaceutical formulation by addition of stock solutions of the respective excipients or by an appropriate conditioning buffer and homogenization of the liquid pharmaceutical formulation is homogenized by mixing.
17. A vial comprising the pharmaceutical formulation of any one of claims 1 to 9.
- 20 18. A prefilled syringe comprising the pharmaceutical formulation of any one of claims 1 to 9.
19. A lyophilised form of the liquid pharmaceutical formulation of any one of claims 1 to 9.